

## Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer

Strasbourg, France, October 7, 2024, 8 a.m. CET – **Transgene (Euronext Paris: TNG)**, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a **poster highlighting median 24-month follow up from the ongoing randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050 at the 39<sup>th</sup> Society for ImmunoTherapy of Cancer (SITC) annual meeting**. This presentation will emphasize efficacy and disease-free survival outcomes in patients with head and neck cancers. SITC annual meeting will take place in Houston, Texas, USA, from November 6 to 10, 2024.

The abstract will be available on the SITC website on November 5, 2024, from 3 p.m. CET.

### Poster details

**Title: “Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)”.**

- Poster and abstract number: 650
- Date and Time: Thursday, November 7, 2024 at 4 p.m. CET
- Author : C. Le Tourneau

TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s *myvac*<sup>®</sup> technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. TG4050 is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers ([NCT04183166](#)).

Transgene previously presented data in April 2024, that showed that all patients who received TG4050 remained disease-free after a median follow-up of 18.6 months, comparing favorably to the observational arm which saw 3 out of 16 patients relapse during the same time period.

Transgene and NEC are continuing the joint development of TG4050 in this indication with a Phase II extension of the trial, which is currently enrolling patients.

\*\*\*

## About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the *myvac*<sup>®</sup> platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO<sup>®</sup> viral backbone.

With Transgene's *myvac*<sup>®</sup> platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*<sup>®</sup> approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO<sup>®</sup>, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: [www.transgene.fr](http://www.transgene.fr)

Follow us on social media: X (previously-Twitter): [@TransgeneSA](https://twitter.com/TransgeneSA) – LinkedIn: [@Transgene](https://www.linkedin.com/company/transgene)

## Contacts

### Transgene Contacts:

#### Media:

#### Caroline Tosch

Corporate Communications Manager

+33 (0)3 68 33 27 38

[communication@transgene.fr](mailto:communication@transgene.fr)

#### Lucie Larguier

Chief Financial Officer

#### Nadege Bartoli

IR Analyst & Financial Communications Officer

+33 (0)3 88 27 91 03 /00

[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

### Transgene Media Contact:

#### MEDISTRAVA

Sylvie Berrebi/Frazer Hall

+ 44 (0) 203 928 6900

[transgene@medistrava.com](mailto:transgene@medistrava.com)

## Disclaimer

*This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website ([www.transgene.fr](http://www.transgene.fr)). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.*